Testing effectiveness (Phase 2)Study completedNCT01750918What this trial is testingBRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)Who this might be right forCancer Novartis Pharmaceuticals 166
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07699952What this trial is testingFirst-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsWho this might be right forLung Cancer (NSCLC)EGFR Activating MutationHER2 Yongsheng Wang 35
Testing effectiveness (Phase 2)UnknownNCT03382795What this trial is testingRetreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive PatientsWho this might be right forEGFR Positive Non-small Cell Lung Cancer Korea University Guro Hospital 63
Testing effectiveness (Phase 2)UnknownNCT03994393What this trial is testingNon Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.Who this might be right forEGFR Mutant Advanced Non Small Cell Lung Cancer University of Sydney 100
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970What this trial is testingHERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyWho this might be right forNonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion Daiichi Sankyo 586
Testing effectiveness (Phase 2)Study completedNCT01866410What this trial is testingCabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerWho this might be right forRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Ended earlyNCT00087269What this trial is testingErlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionWho this might be right forStage IA Non-small Cell Lung CancerStage IB Non-small Cell Lung CancerStage IIA Non-small Cell Lung Cancer+2 more National Cancer Institute (NCI) 110
Testing effectiveness (Phase 2)Study completedNCT00314262What this trial is testingPhase I/II Study of Chemoprevention With EGFR and COX-2 InhibitorWho this might be right forPrecancerous Conditions Emory University 17
Not applicableStudy completedNCT02418234What this trial is testingT790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI FailureWho this might be right forNon-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic First People's Hospital of Hangzhou 314
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717What this trial is testingOsimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerWho this might be right forNon-Small Cell Lung Cancer Dana-Farber Cancer Institute 48
Testing effectiveness (Phase 2)Study completedNCT01833572What this trial is testingPreoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)Who this might be right forNon-small-cell Lung Cancer Fudan University 36
Early research (Phase 1)Study completedNCT02374645What this trial is testingA Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCWho this might be right forNon-Small Cell Lung Cancer Hutchison Medipharma Limited 64
Not applicableLooking for participantsNCT05559645What this trial is testingAssessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)Who this might be right forNon Small Cell Lung Cancer Peking Union Medical College Hospital 180
Testing effectiveness (Phase 2)Study completedNCT01802632What this trial is testingAZD9291 First Time In Patients Ascending Dose StudyWho this might be right forAdvanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer AstraZeneca 603
Early research (Phase 1)Ended earlyNCT01441128What this trial is testing-02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small Cell LungAdenocarcinomaCarcinoma, Squamous Cell+1 more National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT00600587What this trial is testingInduction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)Who this might be right forCarcinoma, Non-Small-Cell Lung Guangdong Provincial People's Hospital 24
Testing effectiveness (Phase 2)Ended earlyNCT00694603What this trial is testingCetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior TherapyWho this might be right forNon-small Cell Lung Cancer Lecia V. Sequist 56
Testing effectiveness (Phase 2)Looking for participantsNCT06741085What this trial is testingStereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the BrainWho this might be right forNon Small Cell Lung Cancer Metastatic Memorial Sloan Kettering Cancer Center 56
Testing effectiveness (Phase 2)Study completedNCT04426825What this trial is testingAtezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Hoffmann-La Roche 23
Not applicableStudy completedNCT00922025What this trial is testingMulticentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male PatientsWho this might be right forNon Small Cell Lung Cancer AstraZeneca 186